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EXPERIMENTAL STUDIES 
Mexiletine Antagonizes Effects of Sotalol on QT Interval Duration and 
Its Proarrhythmic Effects in a Canine Model of Torsade de Pointes 
FR I~Dt~RIQUE CHt~ZALVIEL -GUILBERT,  PHD, JEAN-MARC DAVY,  MD,  PHD,* 
JEAN-MARIE  POIR IER,  PHD, JACQUES WEISSENBURGER,  MD,  PHD¢ 
Paris and Montpellier, France 
Objectives. The arrhythmogenic and electrophysiologic proper- 
ties of sotalol, a class III antiarrhythmic drug, administered alone 
and in combination with mexiletine, a class I antiarrhythmic drug, 
were compared in conscious dogs predisposed to torsade de 
pointes arrhythmias. 
Background. The utility of sotalol is limited by proarrhythmia 
related to excessive delays in repolarization. The addition of 
mexiletine may limit the risk of torsade de pointes because it 
reduced in vitro the sotalol.induced increase in action potential 
duration. 
Methods. Two studies were performed in eight hypokalemic 
dogs (plasma potassium level _<3.2 retool/liter) with chronic 
atrioventricular block (mean ventricular cycle length, RR 
1,100 ms) at 3-day intervals using a crossover protocol. Intrave- 
nous sotalol (4.5 + 1.5 mg/kg body weight per h) alone was given 
for 2 h, or, on another day, an intravenous mexiletine infusion 
(4.5 + 1.5 mg/kg per h) was begun 30 rain before sotaloi infusion. 
Spontaneous ventricular cycle length and QT interval and yen- 
tricular effective refractory period at the 1,000-ms pacing cycle 
length were measured at baseline and 30 rain after the onset of 
each drug infusion. The electrocardiogram (ECG) was continu- 
ously monitored for torsade de pointes. 
Results. Sotalol plus mexiletine and sotalol alone had a signif- 
icant (p < 0.05) and similar effect on ventricular cycle length 
(+800 -+ 93 vs. +690 ± 104 ms [mean ± SEM]) and ventricular 
effective refractory period (+20 ± 4 vs. +25 + 4 ms), but sotalol 
plus mexiletine had a lesser effect on QT interval (+20 ± 6 vs. 
+50 ± 8 ms, p < 0.05). Torsade de pointes is less frequent (one 
of eight dogs vs. six of eight dogs, p = 0.02) with sotalol plus 
mexiletine than with sotalol alone. 
Conclusions. The coadministration of a class Ib agent can 
reduce the proarrhythmic potential of a class III drug in experi- 
mental animals predisposed to torsade de pointes arrhythmias 
and further suggests the clinical utility of such a strategy. 
(J Am CoU Cardiol 1995;26:787-92) 
Sotalol is a beta-adrenergic blocking drug exhibiting so-called 
class III properties (i.e., it prolongs the duration of the cardiac 
action potential), as clearly demonstrated in vitro (1,2) and in 
vivo in both animal models (3) and in humans (4). This effect 
is responsible for the occurrence of long QT-related proar- 
rhythmic events, the most severe of which is torsade de pointes. 
This ventricular arrhythmia occurs particularly during renal 
failure, hypokalemia and bradycardia and in the presence of a 
prolonged QT interval (4-7). There is also evidence that 
sotalol produces early afterdepolarizations i  Purkinje fibers 
(8,9). Torsade de pointes can be readily produced by sotalol in 
hypokalemic dogs with atrioventricular (AV) block (10,11). 
Recent in vivo and clinical studies (12-14) have suggested 
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that the antiarrhythmic effectiveness of sotalol could be en- 
hanced by the addition of a class I drug, particularly mexiletine, 
a class Ib antiarrhythmic drug. Another possible advantage 
from such a combination would be a decrease in the long 
QT-related proarrhythmic effects of sotalol. In vitro studies 
have demonstrated (9,15) that 3 /xmol/liter of mexiletine 
antagonizes the prolongation in action potential duration of 
Purkinje fibers induced by 12 to 50 /xmol/fiter of sotalol. 
Furthermore, 10 /xmol/liter of mexiletine suppressed early 
afterdepolarizations i duced by 30 ~mol/liter of sotalol, pro- 
posed to be involved in the mechanism of torsade de pointes 
(9). Mexiletine might thus limit the risk of ventricular arrhyth- 
mias, such as torsade de pointes, produced by sotalol therapy 
in patients; however, this possibility remains to be substanti- 
ated by in vivo studies. Therefore, we sought o compare the 
electrophysiologic and proarrhythmic effects of sotalol admin- 
istered alone or in combination with mexiletine in a well- 
established canine model of torsade de pointes from our 
laboratory (10-16). 
Methods  
Animal preparation. Mongrel dogs (mean [_+ SEM] weight 
19.0 _+ 1.4 kg) underwent operation with pentobarbital nes- 
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thesia (30 mglkg body weight) with complementary doses 
(6 mg/kg) given as needed, as previously described (10). 
Briefly, surface lectrocardiographic (ECG) leads I, II and lII 
were continuously displayed. The heart was exposed through a
right thoracotomy in the fourth intercostal space and sus- 
pended in a pericardial cradle. Two wire electrodes (Ethicon, 
FEP 13, Ethnor) were sutured to the epicardial surface of the 
right atria and four to the anterior surface of the right and left 
ventricles. Several electrodes were sutured to keep at least wo 
electrodes available for pacing several weeks after the opera- 
tion. The wires were exteriorized through a subcutaneous 
tunnel in the interscapular region. Complete AV block was 
created by injections of 0.1 ml of 37% formaldehyde into the 
upper part of the ventricular septum. The thoracotomy was 
closed in layers, and two ventricular wires were connected to a 
2,000-ms cycle length demand pacemaker (Cordis 236, 237 or 
402 implantable models) placed in the pocket of a jacket. The 
dogs were given oxacillin (Bristopen, Bristol-Myers) or amoxi- 
cillin (Clamo~l, Beecham), 500 mg intravenously, infused 
slowly during the operation, followed by 500 mg given subcu- 
taneously daily for 3 days. 
The dogs were allowed to recover for 15 days and were then 
given oral diuretic drugs, including furosemide (200 rag/day) 
and hydrochlorothiazide (25 to 50 mgjday), to induce hypoka- 
lemia (plasma potassium level ---3.2 retool/liter). The plasma 
levels of potassium, sodium and creatinine were measured 
regularly in all dogs. Saline solution (500 to 1,000 ml 0.9% 
NaC1) was infused when the creatinine level exceeded 100 
retool/liter to prevent severe functional renal failure. 
Electrophysiologic study. Eight dogs were brought o the 
electrophysiolo~, laboratory for study 112 +_ 18 days (mean _+_ 
SEM) after the induction of AV block. They were conscious 
and kept quiet while recumbent. They were given a saline 
infusion through aperipheral vein. The ECG was continuously 
monitored with three standard leads (I, II, III) and two 
precordial eads (V 1, V:). The atrial electrodes were used to 
record the bipolar atrial deflection when necessary. The ven- 
tricular electrodes were disconnected from the external pace- 
maker and connected toa programmable stimulator (Explorer 
1500, VPA Medical) for electrophysiologic measurements. 
Measurements were made at baseline (20 rain after installa- 
tion) and after the start of infusion of drugs and included 
baseline ventricular (RR) and atrial (AA) cycle lengths, the 
diastolic excitability threshold and, after 3 rain of pacing at 60, 
120 and 180 beats/rain, the QRS duration, the QT interval and 
the ventricular effective refractory period. The QT intervals 
were measured during pacing between the onset of the stimu- 
lation artifact and the end of the T wave (and thus could 
include a U wave), as previously described (Ref. 16). The 
ventricular effective refractory period was measured using the 
extrastimulus technique: a train of eight basic stimuli (S1) was 
followed by a premature stimulus ($2), and the process was 
repeated after shortening the S1-S 2 interval by 10 ms until 
failure to capture occurred. The ventricular efractory period 
was defined as the longest SI-S2 paced interval not capturing 
the ventricle. The stimuli were constant-current 2-ms pulses at 
twice the diastolic excitability threshold. Recordings were 
made with an ink-jet recorder (Mingograph 81, Elema Schoen- 
ander) with a 100-mm/s paper speed. Before, between and 
after electrophysiologic measurements, the ECG was continu- 
ously recorded throughout the time of drug infusion with a 
paper speed of 25 mm/s for detection of ventricular arrhyth- 
mias. Torsade de pointes was defined as polymorphic ventric- 
ular tachycardia of eight or more complexes, with rotation of 
the QRS spikes with or without degeneration into ventricular 
fibrillation. 
Any electric defibrillation was carried out with a minimal 
delay, but only after the dog became unconscious, using 
external 8-cm paddles (Minidef SB, Odam). 
The dogs were cared for in compliance with "The European 
Convention for the Protection of Vertebrate Animals Used for 
Experimental nd Other Scientific Purposes" (European Com- 
munity Directive No. 86/609/CEE). 
Protocol. Each hypokalemic dog underwent two experi- 
ments in a randomized order 48 h apart, one with sotalol plus 
mexiletine (combination experiment) and the other with so- 
talol plus saline solution (sotalol-alone xperiment). A plasma 
potassium level of 2.5 to 3.2 retool/liter was the only precon- 
dition for either experiment. The mexiletine infusion (combi- 
nation experiment) was begun first and continued throughout 
the experiment. Sotalol infusion was begun 30 rain later and 
continued for 2 h. Electrophysiologic measurements were 
made at baseline, 10 rain before sotalol infusion and after 
30 rain of sotalol infusion. Ventricular arrhythmia monitoring 
was performed uring a 30-min baseline period and through- 
out the drug infusion (150 min). In sotalol-alone xperiments, 
mexiletine was replaced by saline solution. 
Drugs. The antiarrhythmic drugs used were mexiletine 
(Mexitil IV, Boehringer) and oL-sotalol chlorhydrate (Bristol). 
Other drugs were furosemide (Hoechst) and hydrochlorothia- 
zide (Esidrex, Ciba Geigy). Capsules of 200 mg of furosemide 
were prepared locally. All doses are expressed as free base. 
Antiarrhythmic drugs were administered intravenously as a 
10-rain loading dose begun simultaneously with the mainte- 
nance infusion (12 ml/h). The loading doses and infusion rates 
for both groups were 4.5 mg/kg + 1.5 mg/kg per h for sotalol 
and 4.5 mg/kg + 1.5 mg/kg per h for mexiletine. 
Laboratory measurements. Blood samples were taken 
from a peripheral vein for measurement of plasma electrolyte 
levels (potassium, sodium, creatinine) at the beginning of each 
experiment. Samples were also taken for determination f drug 
levels immediately after the 30- and 90-rain electrophysiologic 
measurements. Plasma sotalol levels were measured by high 
performance liquid chromatography (17). Results are ex- 
pressed as free base. Mexiletine plasma levels were not as- 
sessed for technical reasons. 
Statistical analysis. Results are expressed as mean value + 
SEM. The significance l vel of probabilities was set at 0.05. 
Comparison among groups was performed to analyze the 
electrophysiologic effects of the treatment within each experi- 
ment compared with baseline and to compare the effects of 
sotalol alone or combined with mexiletine, using analysis of 
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Table 1. Electrophysiologic Effects of Sotalol Alone or in Combination With Mexiletine (mean _+ SEM) 
Sotalol-Alone Experiment Combination Experiment 
Sotalol + Sotalol + 
Baseline NaC1 NaC1 Baseline Mexiletine Mexiletine 
RR (ms) 1,133 + 117 41 + 6 690 ± 104' 1,103 ± 83 65 ± 24 800 ± 93* 
AA (ms) 487 + 45 83 _+ 27 168 ± 66* 521 ± 70 13 ± 42 121 + 39 
QRS60 (ms) 88 + 3 0.1 _+ 0.5 1.5 + 1.6 90 + 6 -0.9 + 1.1 -2.1 _+ 1.0 
QRS120 (ms) 87 + 4 2.3 + 1.1 2.5 _+ 1.4 84 = 5 0.0 _+ 0.0 2.0 _+ 2.1 
QRS180 (ms) 89 + 4 1.4 + 0.9 2.0 ± 1.4 85 + 5 0.8 + 1.1 1.3 ± 2.0 
QT60 (ms) 330 + 11 1.3 + 3.4 50 ± 8.0* 331 ± 13 -15 ± 3.H 20 ± 6.0.~ 
QTI20 (ms) 284 ± 8 4.4 ± 1.1 31 ± 4.8* 287 ± 12 1.0 ± 5.2 14 ± 5.2~ 
QTI80 (ms) 259 ± 7 1.9 ± 1.4 16 + 3.7 255 ± 11 -2.2 ± 1.8 11 _+ 3.7~. 
VERP60 (ms) 171 ± 6 -0.6 _+ 2.4 25 _+ 4.1" 174 _+ 6 -0.6 ± 1.8 20 ± 3.5* 
VERP120 (ms) 148 _+ 4 0.0 ± 0.9 21 _+ 3.5* 149 _+ 4 0.0 ± 3.6 19 _+ 4.7* 
VERP180 (ms) 131 ± 3 3.6 + 1.8 19 _+ 2.0* 135 _+ 3 0.0 + 2.2 13 _+ 3.6* 
*p -< 0.05 versus baseline, tp -< 0.05 versus aline solut on. +p -< 0.05 versus ota ol. QRS60 (QRS120, QRS180), QT60 (QT120, QT180) and VERP60 (VERP120, 
VERP180) = QRS interval, QT interval and ventricular effective refractory, period measured after 3 min of pacing at 60, 120 and 180 beats/rain, respectively. 
variance for repeated measures, with post hoc pairwise com- 
parisons using Bonferroni's t test. One way analysis of variance 
was used to test regression between the frequency and the 
sotalol effects on repolarization. The numbers of dogs in each 
group developing torsade de pointes were compared using the 
Fisher exact est. 
Results 
Electrophysiologic study. The baseline electrophysiologic 
variables were similar for the two experiments (first and fourth 
columns of Table 1). The plasma levels of sotalol were also 
similar: 3.02 _+ 0.14 and 3.12 _+ 0.22/~g/ml in the sotalol-alone 
experiment and the combination experiment, respectively. The 
electrophysiologic effects of saline solution, mexiletine and 
sotalol alone or combined with mexiletine are summarized in
Table 1. 
Mexiletine given alone had a rate-dependent effect on the 
QT interval: The decrease in QT interval measured at 60 
beats/rain was significantly (p = 0.03) different from that 
measured after the saline infusion, but no difference was 
observed at the faster ates. No change in QRS duration was 
observed after mexiletine at the pacing rates used in this study. 
Sotalol given alone prolonged ventricular (+63 _+ 11%) and 
atrial (+43 _+ 17%) cycle lengths. A significant (p -> 0.001) 
relation between the sotalol-induced prolongation of the QT 
interval and pacing rate was demonstrated (Fig. 1): QT interval 
was increased by 16 _+ 3%, 11 _+ 2% and 6 _+ 1% at 60, 120 and 
180 beats/rain, respectively. Ventricular efractory periods 
were also increased after sotalol but no rate dependence was 
demonstrated (14 + 2%, 16 _ 1% and 15 _+ 2% at 60, 120 and 
180 beats/rain, respectively). 
Sotalol combined with mexiletine prolonged the ventricular 
cycle length (+74 + 9%) similarly to sotalol given alone. An 
increase in the atrial cycle length was also observed (30 _+ 
10%) but was not significant (p = 0.09). Prolongation of the 
QT interval measured at 60 and 120 beats/rain i  the sotalol- 
alone experiment was not significant in the sotalol plus mexi- 
letine experiment. As a consequence, no rate dependence of
sotalol effects could be demonstrated in the combination 
experiment (p = 0.21) (Fig. 1). On the contrary, the increase in 
ventricular refractory period was significant and similar to that 
observed after sotalol alone (-12% regardless of pacing rate). 
Arrhythmogenic effects. The proarrhythmic a tions of so- 
talol given alone and combined with mexiletine are shown in 
Figures 2 and 3. 
Figure 1. Example of the relation between QT interval and 
heart rate at baseline, after sotalol alone and after the 
combination fsotalol plus mexiletine observed inthe same 
dog. QT60, QT120, QT180 = QT interval measured after 
3 rain of pacing at 60, 120 and 180 beats/min, respectively. 
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Figure 2. Representative torsade de pointes obse~'ed uring sotalol- 
alone infusion (middle tracing). Sotalol has a slowing effect on the 
ventricular escape rhythm compared with that at baseline (top trac- 
ing). During sotalol plus mexiletine combination i fusion, no arrhyth- 
mias are seen despite a similar bradycardia {bottom tracing). 
Only one dog presented bigeminal ventricular premature 
beats during the 2(1 min of baseline measurements and during 
saline infusion (sotalol-alone xperiment). No proarrhythmic 
events were detected uring mexiletine infusion in either dog 
(combination experiment). The number of sotalol-induced 
torsade de pointes was significantly reduced by combination 
with mexiletine: six of eight dogs developed torsade de pointes 
after sotalol alone but only one of eight dogs (p = 0.02) after 
sotalol plus mexiletine. A total of 15 torsade de pointes were 
observed uring the study: 14 after sotalol alone versus 1 after 
the combination. Four of 15 torsade de pointes degenerated 
into ventricular fibrillation (3 after sotalol alone, 1 after sotalol 
plus mexiletine). Torsade de pointes that stopped spontane- 
ously included between 8 and 185 beats (mean 35 _+ 16 beats) 
and had a mean cycle length of 163 + 6 ms. 
Discuss ion  
The present study showed that mexiletine antagonizes 
sotalol effects on QT-interval duration and prevents, at least in 
part, its proarrhythmic effects in conscious hypokalemic dogs 
with AV block. 
Electrophysiologic effects. The electrophysiologic effects 
of sotalol in the present study are consistent with published 
reports (10,11,18) demonstrating in vitro or in vivo a prolon- 
gation of ventricular epolarization and the occurrence of 
torsade de pointes after sotalol. These effects are favored by a 
slowed rate, as shown in the present study and in numerous in 
vitro and clinical studies (18-20). 
The only modification of ECG intervals demonstrated after 
mexiletine alone was a slight but significant decrease in QT 
interval duration observed at the 60-beats/rain pacing rate 
( 15 ms). Other eleetrophysiologic variables (ventricular cycle 
length, QRS interval, ventricular effective refractory period) 
were unchanged, which is consistent with previous tudies in 
dogs (21) and in humans (22,23). The decrease in QT interval 
can be compared with the shortening of action potential 
duration described in canine and porcine Purldnje fibers (9,15) 
and in papillary muscle (24,25). 
Rate dependence of the effect of mexiletine on the QT 
interval was demonstrated in the present study because no 
change in QT interval was observed at 120 and 180 beats/rain, 
whereas a significant shortening of the QT interval was de- 
tected at 60 beats/rain. This finding is consistent with those of 
previous in vitro studies (24,26). Varro et al. (24) demon- 
strated a 40% decrease in the action potential duration 
(APD90) at a 5,000-ms cycle length in Purkinje fibers, which 
progressively decreased with decreasing cycle length to a value 
of t6% at 300 ms. Similar reverse-use dependence was shown 
in ventricular muscle (24) because a significant effect was 
detected only >2,000 ms. To our knowledge, no previous in 
vivo studies have evaluated the rate dependence of mexil- 
etine's effects on repolarization. 
The effects measured with the combined treatment are a 
result of opposing rate-dependent actions on repolarization. 
The slower the heart rate, the greater the sotalol-induced 
prolongation of ventricular epolarization. By contrast, the 
slower the heart rate, the greater the mexiletine-induced 
shortening of ventricular repolarization, and thus more mexi- 
letine is able to antagonize the effects of sotalol on the QT 
interval. Thus, the combination fails to change the QT interval 
significantly at all rates, and rate-dependent effects on repo- 
larization are no longer observed. This electrophysiologic 
antagonism was associated with a noticeable decrease in the 
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Figure 3. Ventricular arrhythmias detected uring sotalol 
alone and the combination experiment. Number of dogs with 
ventricular arrhythmias i  indicated by different bar segments 
and identified by corresponding segment pattern. NoA = no 
arrhythmias; PVB = premature ventricular beats; RPB = 
repetitive premature beats; TdP= torsade de pointes; TVp = 
polymorphic ventricular tachycardia. 
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number of dogs that developed torsade de pointes after sotalol 
(one of eight after sotalol plus mexiletine vs. six of eight after 
sotalol alone). These results are consistent with in vitro studies 
(9,15). Berman et al. (15) showed that low concentrations of
mexiletine (3.1 /xmol/liter) could antagonize the sotalol- 
induced prolongation of the action potential in Purkinje fibers. 
This antagonism remained when higher doses of sotalol were 
added to the preparation, which is consistent with the obser- 
vations of Varro et al. (9,27) that mexiletine or lidocaine 
abolished the occurrence of early afterdepolarizations i duced 
by sotalol at slow rates ( -  15 beats/min). To our knowledge, no 
in vivo experiments have studied the effects of the sotalol- 
mexiletine combination on ventricular epolarization. Mexil- 
etine has been shown to antagonize the action potential 
duration prolongation produced by other drugs. Costard- 
Jaeckle et al. (28), testing the combination of quinidine and 
mexiletine, showed with monophasic action potential record- 
ings that the so-called class III effects of quinidine in canine 
ventricular myocardium invivo are antagonized by mexiletine. 
A similar observation has also been made in humans (29). 
Proarrhythmic effects. The ability of class Ib antiarrhyth- 
mic drugs to terminate torsade de pointes has not been clearly 
demonstrated in humans. Their use has been recommended in 
cases of drug-induced torsade de pointes (30) or long QT 
syndrome-related arrhythmias (31). Lidocaine is the most 
often tested class Ib agent, but its effectiveness i  variable, and 
several cases of torsade de pointes recurrence after lidocaine 
have been reported (31-34). Little is known about mexiletine. 
Only one case has been reported (31) suggesting the efficacy of 
mexiletine for avoiding torsade de pointes recurrence during 
several weeks, but it was not established that mexiletine 
prevented the arrhythmias or that the arrhythmias disappeared 
as a result of withdrawal of procainamide. 
Ionic mechanisms explaining the effectiveness ofmexiletine 
in suppressing torsade de pointes can be suggested. 1) Mexil- 
etine produced a shortening of cardiac action potential. Ac- 
cording to Hondeghem's modulated receptor hypothesis, 
Hafner et al. (18) suggested that the action of sotalol is 
controlled by the integral open time of potassium channels, 
which is strongly dependent on action potential duration. Long 
action potentials provide a greater opportunity for sotalol 
action on activated channels. As a consequence, the shortening 
of action potential plateau induced by mexiletine would impair 
the potency of sotalol on ventricular repolarization. 
2) Mexiletine could limit the genesis of early afterdepolar- 
izations, which are involved in the mechanism of torsade de 
pointes occurrence. These may result when inward depolariz- 
ing currents exceed the outward currents, for instance, because 
the inward sodium or calcium ion currents are enhanced 
(35,36). The slow inward calcium channel blockade produced 
by mexiletine (37) may contribute to the limitation of the 
favorable effects of sotalol on early afterdepolarizations. A 
window sodium ion current blockade could also be involved 
because mexiletine is a sodium channel blocker (38,39). 
Conclusions. Mexiletine prevents the occurrence of so- 
talol-induced torsade de pointes in a significant number of 
conscious hypokalemic dogs with AV block, by limiting pro- 
longation of the QT interval due to sotalol. To our knowledge, 
this study is the first to demonstrate this type of favorable 
interaction in a canine model of torsade de pointes arrhyth- 
mias. On the basis of these results, the combination of sotalol 
plus mexiletine merits erious consideration for patients at risk 
of the acquired long QT syndrome. It would be of great clinical 
value to determine whether combination treatment can pre- 
serve the therapeutic efficacy of sotalol while limiting the risk 
of proarrhythmia n controlled trials. 
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